ELDRUG S.A. Information

Eldrug is a research Spin-off of High Technology company which was established in June of 2006 with an investment of €1.000.000 and a re-investment of another €1.000.000 from the Greek Pharmaceutical Company VIANEX owned by Paul, Constantine and Athanasios Giannakopoulos and a grant of €720.000 from the Greek Ministry of Development. The goal of ELDRUG is the Research and Development of Innovative Anti-hypertensive Products, including the most potent under the name of ELSARTAN. The spin-off with experience and know-how of its researchers in the Planning and Discovery of Pharmaceutical Products, possesses the rights of ELSARTAN and relative synthetic derivatives. Created by researchers including John Matsoukas, Professor of Chemistry at the University of Patras, Michael Maragoudakis, Emeritus Professor of Medicine at the University of Patras, Haralambos Gavras, Professor of Medicine at Boston University, Dimitrios Vlahakos, Associate Professor of Medicine at the University of Athens and younger researchers who are involved in the research project. From January 2010, ELDRUG incorporated the assets of a highly innovative project, the “Elmyelin”, aimed at patients suffering from multiple sclerosis. These products are organic peptide compositions, similarly immuno dominant of the epitopes of Myelin protein which is involved in the pathology of multiple sclerosis and is the result of long research at the University of Patras.